Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK-011 plus best supportive care vs placebo plus best supportive care in FGF19-overexpressing advanced or unresectable hepatocellular carcinoma
CTR20251382Phase 2Active
- Sponsor
- Abbisko Therapeutics
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irpagratinib in hepatocellular carcinoma (HCC), sponsored by Abbisko Therapeutics. Started Jun 2025; status: active.
02
Drugs
irpagratinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20251382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251382.